Dementia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 18 Jun 2026 04:08:01 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Dementia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Using [18F]DED PET imaging to study brain changes in patients with Alzheimer’s disease, CADASIL, and other forms of dementia. https://clinicaltrials.eu/trial/using-18f-ded-pet-imaging-to-study-brain-changes-in-patients-with-alzheimer-s-disease-cadasil-and-other-forms-of-dementia/ Wed, 29 Apr 2026 15:09:38 +0000 https://clinicaltrials.eu/trial/using-18f-ded-pet-imaging-to-study-brain-changes-in-patients-with-alzheimer-s-disease-cadasil-and-other-forms-of-dementia/ This study focuses on understanding brain changes in people living with various forms of Dementia, which is a group of symptoms that affect memory, thinking, and social abilities. The research includes specific types of the condition such as Alzheimer’s Disease, including cases that are Autosomal Dominant Alzheimer’s Disease, Late onset Alzheimer Disease, and Sporadic early onset Alzheimer Disease. Additionally, the study involves individuals with CADASIL, a rare genetic condition that affects the small blood vessels in the brain. The primary goal is to investigate how certain brain cells called astrocytes react during the progression of these diseases.

To observe these changes, a specialized imaging technique called PET, or positron emission tomography, will be used. During the process, a substance known as [18F]DED will be administered through an intravenous injection, which means it is delivered directly into a vein. This substance acts as a tracer that allows doctors to see specific activities in the brain through medical scans. This imaging process helps to identify how the brain cells are behaving in different stages of neurodegenerative diseases, which are conditions where the nervous system gradually declines over time.

]]> Evaluating the effect of recombinant varicella zoster virus glycoprotein E on the risk of dementia in adults aged 76 years and older https://clinicaltrials.eu/trial/evaluating-the-effect-of-recombinant-varicella-zoster-virus-glycoprotein-e-on-the-risk-of-dementia-in-adults-aged-76-years-and-older/ Wed, 29 Apr 2026 15:09:13 +0000 https://clinicaltrials.eu/trial/evaluating-the-effect-of-recombinant-varicella-zoster-virus-glycoprotein-e-on-the-risk-of-dementia-in-adults-aged-76-years-and-older/ This study is designed to evaluate the effect of the Shingrix vaccine on the risk of developing dementia, a condition that affects memory, thinking, and reasoning skills. The research focuses on whether receiving this vaccine, which is used to prevent Herpes zoster, also helps in preventing a new diagnosis of this brain-related condition in older adults.

Participants in the study will be assigned to receive either the Shingrix vaccine or a placebo. The Shingrix is a recombinant vaccine, which means it is made using a specific piece of the virus to help the body build protection. The placebo used in this trial is a saline solution, which is a simple mixture of salt and water. The medication will be given as an intramuscular injection, meaning it is delivered directly into the muscle.

]]> A Study of Donanemab in People With Early Symptomatic Alzheimer’s Disease https://clinicaltrials.eu/trial/a-study-of-donanemab-in-people-with-early-symptomatic-alzheimers-disease/ Wed, 29 Apr 2026 15:07:45 +0000 https://clinicaltrials.eu/trial/a-study-of-donanemab-in-people-with-early-symptomatic-alzheimers-disease/ This study is looking at Alzheimer’s disease in people who are in the early stages of the condition. Alzheimer’s disease is a brain disorder that gradually affects memory, thinking, and the ability to carry out daily activities. The study will test a medication called donanemab (also known by its code name LY3002813), which is an antibody designed to target a protein called amyloid beta that builds up in the brains of people with Alzheimer’s disease. Some participants will receive donanemab while others will receive placebo. The study will also use special imaging substances called florbetapir (code name LY3078786) and flortaucipir (code name LY3191748) that help doctors see protein deposits in the brain through scanning procedures. Sodium chloride will be used as part of the treatment process.

The purpose of this study is to see whether donanemab can slow down the worsening of symptoms compared to placebo in people with early symptomatic Alzheimer’s disease. The study will measure changes in memory, thinking abilities, and daily functioning over time to determine if the treatment is effective.

During the study, participants will receive the study medication through an infusion into a vein. The treatment will continue for a period of time while doctors monitor how well participants are doing with their memory and daily activities. Participants will need to have a study partner who knows them well and can provide information about any changes in their condition. The study will use brain scans to check for the presence of certain proteins that are associated with Alzheimer’s disease. These scans help doctors understand the extent of the disease and monitor any changes during the study.

]]> Study on Efgartigimod for Patients with Autoimmune Dementia https://clinicaltrials.eu/trial/study-on-efgartigimod-for-patients-with-autoimmune-dementia/ Wed, 29 Apr 2026 15:05:55 +0000 https://clinicaltrials.eu/trial/study-on-efgartigimod-for-patients-with-autoimmune-dementia/ This clinical trial is focused on studying a condition known as autoimmune dementia. This is a type of dementia where the body’s immune system mistakenly attacks healthy brain cells, leading to problems with memory and thinking. The trial will test a treatment called Efgartigimod, which is given as a solution for injection. Efgartigimod is designed to help reduce the immune system’s attack on the brain by blocking a specific protein involved in this process.

The purpose of the study is to see how effective Efgartigimod is over a period of 52 weeks in improving cognitive function, which includes memory and thinking skills, in people with autoimmune dementia. Participants in the study will receive either Efgartigimod or a placebo, which looks like the treatment but does not contain the active substance. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will have regular check-ups to monitor changes in their cognitive abilities and overall quality of life. These assessments will take place at various points, including at the start of the study and then at weeks 13, 27, and 53. The study will also look at changes in certain markers in the blood and cerebrospinal fluid, which is the fluid surrounding the brain and spinal cord, to better understand how the treatment is working. The trial aims to provide valuable insights into the potential benefits of Efgartigimod for people with autoimmune dementia.

]]> Study on the Accuracy of Tau PET ([18F]RO6958948) and Vizamyl (Flutemetamol 18F) in Diagnosing Mild Cognitive Symptoms and Risk of Alzheimer’s Disease https://clinicaltrials.eu/trial/study-on-the-accuracy-of-tau-pet-18fro6958948-and-vizamyl-flutemetamol-18f-in-diagnosing-mild-cognitive-symptoms-and-risk-of-alzheimers-disease/ Wed, 29 Apr 2026 15:05:45 +0000 https://clinicaltrials.eu/trial/study-on-the-accuracy-of-tau-pet-18fro6958948-and-vizamyl-flutemetamol-18f-in-diagnosing-mild-cognitive-symptoms-and-risk-of-alzheimers-disease/ The study focuses on understanding and improving the diagnosis of certain brain disorders known as neurodegenerative disorders. These include conditions like Alzheimer’s disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration, and mild cognitive impairment. The study uses two special substances, Vizamyl and [18F]RO6958948, which are injected into the body to help doctors see changes in the brain using a type of scan called PET (Positron Emission Tomography).

The purpose of the study is to see how well these substances can help identify people who are at risk of developing dementia, a condition that affects memory and thinking. Participants in the study will receive an injection of either Vizamyl or [18F]RO6958948. These substances help highlight areas in the brain that may be affected by the disorders. The study will compare the brain scans of people with these disorders to those of healthy individuals to better understand the differences.

Throughout the study, participants will undergo various tests, including brain scans and cognitive assessments, to monitor their brain health and cognitive function. The study aims to gather information over time to see how these disorders progress and how the substances used in the study can aid in early detection and diagnosis. This research hopes to provide valuable insights into the early stages of these disorders and improve the way they are diagnosed and understood.

]]> Title: Evaluation of lorazepam, pregabalin, and olanzapine in treating agitated behavior in dementia patients who did not respond to standard treatments https://clinicaltrials.eu/trial/study-on-treating-agitated-behavior-in-dementia-patients-using-quetiapine-lorazepam-and-olanzapine/ Wed, 29 Apr 2026 15:04:21 +0000 https://clinicaltrials.eu/trial/study-on-treating-agitated-behavior-in-dementia-patients-using-quetiapine-lorazepam-and-olanzapine/ This study focuses on treating agitated behavior in people with dementia who have not responded well to standard treatments. The research will test three different medications: quetiapine, olanzapine, and lorazepam. These medications belong to a group of drugs called psychotropic drugs, which affect brain function and mental state. The purpose is to determine how well these medications work in controlling agitation symptoms in dementia patients.

During the study, participants will receive either one of the active medications or a placebo. The medications will be given in capsule form and taken by mouth. The treatment period will last for 6 weeks, during which the maximum daily doses will be 50mg for quetiapine, 10mg for olanzapine, or 2mg for lorazepam. To ensure that neither the patients nor the healthcare providers know which treatment is being given, all medications will be placed in identical capsules.

The study will monitor changes in agitated behavior over time using various assessment tools. Healthcare providers will track any side effects that may occur during the treatment period. This research specifically targets nursing home residents who have dementia with agitated behavior and whose doctors have determined they need medication to manage their symptoms.

]]> Study on the Benefits of Amyloid PET Imaging with Florbetaben (18F) and Flutemetamol (18F) for Patients with Various Types of Dementia https://clinicaltrials.eu/trial/study-on-the-benefits-of-amyloid-pet-imaging-with-florbetaben-18f-and-flutemetamol-18f-for-patients-with-various-types-of-dementia/ Wed, 29 Apr 2026 14:26:26 +0000 https://clinicaltrials.eu/trial/study-on-the-benefits-of-amyloid-pet-imaging-with-florbetaben-18f-and-flutemetamol-18f-for-patients-with-various-types-of-dementia/ This clinical trial is focused on studying the benefits of using a special type of brain scan called amyloid PET imaging for people with different types of dementia. Dementia is a condition that affects memory, thinking, and the ability to perform everyday activities. The study includes various forms of dementia, such as Alzheimer’s disease, vascular dementia, and dementia related to other conditions like Parkinson’s disease and HIV. The trial aims to see if amyloid PET imaging can provide better information compared to standard methods without this imaging.

Participants in the study will receive either the amyloid PET imaging or standard diagnostic procedures. The imaging involves using a solution for injection, such as Neuraceq or VIZAMYL, which contains substances like florbetaben (18F) or flutemetamol (18F). These substances help highlight certain areas of the brain during the scan. The study will observe how this imaging affects the management of daily activities and overall quality of life for those with dementia.

The trial will last for several weeks, with follow-up assessments to monitor changes in cognitive performance, quality of life, and any potential side effects. The goal is to determine if amyloid PET imaging can improve the understanding and treatment of dementia compared to current diagnostic methods. Participants will be monitored by healthcare professionals throughout the study to ensure their safety and well-being.

]]> Study on the Use of Flortaucipir for Diagnosing Mild Cognitive Impairment and Dementia in Patients https://clinicaltrials.eu/trial/study-on-the-use-of-flortaucipir-for-diagnosing-mild-cognitive-impairment-and-dementia-in-patients/ Wed, 29 Apr 2026 14:25:35 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-flortaucipir-for-diagnosing-mild-cognitive-impairment-and-dementia-in-patients/ This clinical trial is focused on studying mild cognitive impairment and dementia, which are conditions that affect memory and thinking skills. The study will use a treatment called Flortaucipir, also known by its code name LY3191748. Flortaucipir is a solution for injection that helps in imaging the brain to detect abnormal protein deposits associated with these conditions. The purpose of the study is to evaluate how well this imaging technique, known as tau PET, can improve the accuracy of diagnosing these memory-related conditions and enhance patient care.

Participants in the study will undergo a tau PET scan, which is a type of imaging test that helps doctors see changes in the brain. This test will be compared to other diagnostic methods to see if it provides better information. The study will look at how the use of tau PET affects the diagnosis, the confidence of doctors in their diagnosis, and the management of the patient’s condition. It will also assess how this imaging technique impacts the patient’s wellbeing, including their levels of anxiety and uncertainty.

The study will also explore how tau PET compares to new blood tests and artificial intelligence tools in diagnosing these conditions. The goal is to see if tau PET can offer a more reliable way to understand and manage mild cognitive impairment and dementia, ultimately improving the care and quality of life for patients with these conditions.

]]> Study on Donanemab Dosing for Adults with Early Alzheimer’s Disease https://clinicaltrials.eu/trial/study-on-donanemab-dosing-for-adults-with-early-alzheimers-disease/ Wed, 29 Apr 2026 14:24:36 +0000 https://clinicaltrials.eu/trial/study-on-donanemab-dosing-for-adults-with-early-alzheimers-disease/ This clinical trial is focused on studying the effects of different dosing regimens of Donanemab (also known by its code name LY3002813) in adults with early symptomatic Alzheimer’s Disease. Alzheimer’s Disease is a condition that affects the brain, leading to memory loss and other cognitive difficulties. The study aims to understand how varying doses of Donanemab impact the occurrence of a specific brain change known as ARIA-E, which stands for Amyloid-Related Imaging Abnormality-Edema/Effusion. This change can sometimes be seen in brain scans of people receiving certain treatments for Alzheimer’s Disease.

Participants in the study will receive either Donanemab or a placebo, which is a substance with no active medication. The study will also use a solution called Neuraceq, which contains Florbetaben (18F), a substance used in brain imaging to help visualize certain changes in the brain. Additionally, Sodium Chloride, commonly known as salt water, will be used as a standard solution for infusion. The study will explore how these treatments affect the brain over a period of time, with regular monitoring through brain scans and other assessments.

The purpose of this study is to gather information on the safety and effectiveness of different dosing strategies of Donanemab in reducing amyloid plaques, which are protein deposits in the brain associated with Alzheimer’s Disease. By comparing these strategies, researchers hope to find the most effective way to manage the disease and improve the quality of life for those affected. Participants will be closely monitored throughout the study to ensure their safety and to collect valuable data on the treatment’s impact.

]]> Study on Neflamapimod for Treating Dementia with Lewy Bodies in Patients Aged 55 and Older https://clinicaltrials.eu/trial/study-on-neflamapimod-for-treating-dementia-with-lewy-bodies-in-patients-aged-55-and-older/ Wed, 29 Apr 2026 14:23:50 +0000 https://clinicaltrials.eu/trial/study-on-neflamapimod-for-treating-dementia-with-lewy-bodies-in-patients-aged-55-and-older/ This clinical trial is focused on studying a condition known as Dementia with Lewy Bodies (DLB). DLB is a type of progressive dementia that leads to a decline in thinking, reasoning, and independent function. The study will use a medication called Neflamapimod, which is taken as a capsule by mouth. Neflamapimod is being tested to see if it can help improve symptoms in people with DLB.

The purpose of the study is to evaluate the effectiveness of Neflamapimod compared to a placebo. Participants in the study will be randomly assigned to receive either Neflamapimod or a placebo. The study will last for several weeks, during which participants will take the medication and attend regular check-ups. These check-ups will help researchers monitor the participants’ health and any changes in their condition.

In addition to taking the medication, participants will undergo a special imaging test called a DaTSCAN. This test helps to confirm the diagnosis of DLB by showing changes in the brain. The study aims to see if Neflamapimod can improve scores on a scale that measures dementia symptoms, as well as other tests that assess movement and cognitive abilities. The results of this study will help determine if Neflamapimod is a beneficial treatment for people with DLB.

]]>